Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study

Key Points

• This research aims to evaluate the effectiveness of second-line and subsequent therapies after first-line treatment failure in advanced hepatocellular carcinoma.
• Multicenter prospective cohort study design
• Focus on patients with advanced hepatocellular carcinoma
• Assessment of therapies including lenvatinib and regorafenib
• Evaluation of progression-free survival and overall survival metrics
• Second-line lenvatinib treatment was associated with prolonged progression-free survival
• Third-line regorafenib treatment improved overall survival
• Findings highlight the importance of optimizing sequential treatments for better patient outcomes

Abstract